Barrick Mining Corporation Stock Price, News & Analysis

BioArctic (Nasdaq Stockholm: BIOA) announced on October 14, 2025 that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab for Alzheimer's disease, was selected by TIME as one of the Best Inventions of 2025 in the Medical and Healthcare category.

The selection recognizes the product's innovation and potential impact. Leqembi was developed in collaboration with Eisai, which leads clinical development, regulatory approvals and global commercialization. BioArctic retains rights to commercialize Leqembi in the Nordic region together with Eisai. Prescribing information in the US includes a Boxed WARNING.

Barrick (NYSE:B) will report third quarter 2025 results on Monday, November 10, 2025, with the release timed for 6:00 AM ET. Management will host a live webcast presentation at 11:00 AM ET the same day followed by a Q&A with analysts. Presentation materials will be posted on the company website and a recording of the webcast will be available for replay later on November 10.

BioArctic (NASDAQ: BIOA) partner Eisai launched Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector in the U.S. on October 6, 2025 as a maintenance option for early Alzheimer’s disease (MCI or mild dementia) after an initial 18-month IV induction.

After 18 months of 10 mg/kg IV every two weeks, patients may continue IV every four weeks or switch to a weekly 360 mg at-home subcutaneous injection. The company also launched a Leqembi Companion program with nurse education, financial/insurance support, an injection tracker and an app. Full prescribing information and a boxed warning apply.

B (Barrick) agreed to sell its interests in the Tongon gold mine and related exploration permits in Côte d’Ivoire to Atlantic for up to $305 million. The consideration comprises $192 million cash (including a $23 million shareholder loan repayment within six months) plus up to $113 million in contingent cash payments tied to gold price over 2.5 years and resource conversions over 5 years. Proceeds will be used to strengthen Barrick’s balance sheet. Closing is expected in late 2025, subject to customary conditions including Government of Côte d’Ivoire approval.

Helzberg, a Berkshire Hathaway company (NYSE: BRK), released its 2025 Engagement & Ring Shopping Survey revealing key trends in modern proposals and ring shopping behaviors. The study, surveying 1,000 U.S. adults aged 20-40, found that 83% prefer private proposals, despite 88% planning to share ring preferences beforehand.

The survey highlighted significant generational differences, with Gen Z showing stronger engagement in social media research (79% vs. 63% millennials) and sustainability concerns (88% vs. 81%). Notable findings include an average maximum ring budget of $4,000, with 76% willing to invest more for customization. While 83% value in-store purchasing options, 56% consider online buying important, reflecting evolving shopping preferences.

Barrick Mining Corporation (NYSE:B) announced a significant leadership transition with the immediate appointment of Mark Hill as Group COO and Interim President & CEO, following Mark Bristow's departure after nearly seven years at the helm.

Hill, currently overseeing Barrick's Latam and Asia Pacific regions, brings 30 years of mining industry experience. Under Bristow's leadership since the 2019 Randgold merger, Barrick has returned $6.7 billion to shareholders and reduced net debt by $4 billion. The Board's Search Committee, led by Brett Harvey, has initiated a search for a permanent CEO with support from a leading executive search firm.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has received approval from China's NMPA for Leqembi's (lecanemab) IV maintenance treatment in early Alzheimer's disease. The new approval allows for a maintenance dosing regimen of 10 mg/kg once every four weeks after an 18-month initiation phase of bi-weekly dosing.

Leqembi, initially approved in China in January 2024, is notable as the only approved therapy targeting both amyloid plaque and protofibrils in Alzheimer's disease treatment. The drug was developed through a collaboration between BioArctic and Eisai, based on Professor Lars Lannfelt's research on the Arctic mutation in Alzheimer's disease.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that Australia's Therapeutic Goods Administration (TGA) has approved Leqembi (lecanemab) for treating early Alzheimer's disease. The approval specifically targets adult patients with mild cognitive impairment or mild dementia who are apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology.

This approval follows a review process initiated in March 2025 after an initial rejection in February 2025. Leqembi, developed through collaboration between BioArctic and Eisai, originated from Professor Lars Lannfelt's research on the Arctic mutation in Alzheimer's disease. While Eisai leads global commercialization, BioArctic maintains Nordic region commercialization rights in partnership with Eisai.

Hexagon US Federal, the federal arm of Hexagon, has confirmed its commitment to supporting national security missions amid organizational changes. The company addressed its strategic position following Hexagon's planned spin-off of Octave, expected in early 2026. The spin-off will include Safety, Infrastructure & Geospatial and Asset Lifecycle Intelligence divisions, along with Bricsys and ETQ units.

Hexagon US Federal will maintain a unique dual alignment, supporting both Octave's portfolio and Hexagon's continuing operations. This position enables the company to accelerate growth in SaaS offerings for public safety and geospatial intelligence while supporting established technologies like Leica Geosystems and Position, Navigation and Timing solutions.